CytomX Therapeutics, Inc. reported a significant decline in its financial performance for the third quarter of 2025, with revenues totaling $5.96 million, a decrease of approximately 82% compared to $33.43 million in the same period of 2024. For the nine months ending September 30, 2025, total revenues were $75.54 million, down from $100.01 million in the prior year. The company recorded a net loss of $14.23 million for the quarter, compared to a net income of $5.74 million in Q3 2024. The substantial drop in revenue was attributed to the completion of performance obligations under collaboration agreements, particularly with Bristol Myers Squibb and Amgen, which resulted in no revenue being recognized from these partnerships during the quarter.
In terms of operational changes, CytomX underwent a restructuring plan in January 2025, which led to a workforce reduction of approximately 40%. This decision was made to streamline operations and prioritize investments in key product candidates, specifically CX-2051 and CX-801. The restructuring resulted in total charges of $2.8 million, primarily related to severance payments. The company also reported a decrease in research and development expenses, which fell to $15.30 million for the quarter, down from $21.37 million in Q3 2024, reflecting reduced spending on certain programs.
CytomX's cash and cash equivalents stood at $34.19 million as of September 30, 2025, a decrease from $38.05 million at the end of 2024. The company also reported short-term investments of $109.44 million, a significant increase from $62.57 million at the end of the previous fiscal year. The total assets of the company rose to $158.25 million, compared to $120.53 million at the end of 2024. The increase in short-term investments was primarily due to proceeds from a public offering completed in May 2025, which generated approximately $93.4 million in net proceeds.
Looking ahead, CytomX anticipates that its existing capital resources will be sufficient to fund operations into the second quarter of 2027. However, the company acknowledges the need for additional funding to support ongoing clinical trials and the development of its product candidates. The future financial outlook remains uncertain, as the company may need to raise substantial additional funds to advance its product candidates and achieve its strategic goals. The management has indicated that the timing and amount of future capital requirements will depend on various factors, including the progress of clinical trials and the success of collaborations with partners.
CytomX continues to focus on its proprietary PROBODY therapeutic technology platform, which aims to develop conditionally activated biologics for cancer treatment. The company is currently advancing its clinical-stage product candidates, including CX-2051, which targets epithelial cell adhesion molecule (EpCAM), and CX-801, a masked version of interferon alpha-2b. The success of these candidates in clinical trials will be critical for the company's future growth and ability to generate revenue.
About CytomX Therapeutics, Inc.
CytomX Therapeutics is a biopharmaceutical company specializing in developing novel, conditionally activated biologics for cancer treatment. Its PROBODY platform enables targeted therapies that activate within the tumor microenvironment, reducing systemic toxicity. The company focuses on antibody-drug conjugates, T-cell engagers, immunotherapies, and mRNA, collaborating with major pharma partners to address unmet oncology needs through innovative, localized biologic drugs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.